NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)
McNamara, Mairead G Goyal, L. Doherty, M. Springfeld, C. Cosgrove, D. Sjoquist, K. M. Park, J. O. Verdaguer, H. Braconi, C. Ross, P. J.
McNamara, Mairead G
Goyal, L.
Doherty, M.
Springfeld, C.
Cosgrove, D.
Sjoquist, K. M.
Park, J. O.
Verdaguer, H.
Braconi, C.
Ross, P. J.
Citations
Altmetric:
Abstract
Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal of NUC-1031/cisplatin in the Phase Ib ABC-08 study suggested that this combination may represent a more efficacious therapy than gemcitabine/cisplatin for patients with aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients /=18 years with untreated histologically/cytologically-confirmed aBTC (including cholangiocarcinoma
Description
Date
2020
Publisher
Collections
Keywords
Type
Article
Citation
M. G. McNamara, L. Goyal, M. Doherty et al. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncol. 2020;16(16):1069-1081.